title: Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins.
abstract: Lethal hepatitis can be induced by an agonistic anti-Fas Ab in normal mice or by TNF in mice sensitized to d -(+)-galactosamine or actinomycin D. In all three models, we found that apoptosis of hepatocytes is an early and necessary step to cause lethality. In the three models, we observed activation of the major executioner caspases-3 and -7. Two acute-phase proteins, alpha1-acid glycoprotein and alpha1-antitrypsin, differentially prevent lethality: alpha1-acid glycoprotein protects in both TNF models and not in the anti-Fas model, while alpha1-antitrypsin confers protection in the TNF/d -(+)-galactosamine model only. The protection is inversely correlated with activation of caspase-3 and caspase-7. The data suggest that activation of caspase-3 and -7 is essential in the in vivo induction of apoptosis leading to lethal hepatitis and that acute phase proteins are powerful inhibitors of apoptosis and caspase activation. Furthermore, Bcl-2 transgenic mice, expressing Bcl-2 specifically in hepatocytes, are protected against a lethal challenge with anti-Fas or with TNF/d -(+)-galactosamine, but not against TNF/actinomycin D. The acute-phase proteins might constitute an inducible anti-apoptotic protective system, which in pathology or disturbed homeostasis prevents excessive apoptosis.
authors.affiliation: Department of Molecular Biology, Flanders Interuniversity Institute for Biotechnology, University of Ghent, Belgium.
authors.forename: W
authors.initials: W
authors.lastname: Van Molle
authors.forename: G
authors.initials: G
authors.lastname: Denecker
authors.forename: I
authors.initials: I
authors.lastname: Rodriguez
authors.forename: P
authors.initials: P
authors.lastname: Brouckaert
authors.forename: P
authors.initials: P
authors.lastname: Vandenabeele
authors.forename: C
authors.initials: C
authors.lastname: Libert
mesh_terms: D000209:Acute-Phase Proteins / Q000494:pharmacology*; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D017209:Apoptosis; D061945:Caspase Inhibitors; D020169:Caspases / Q000378:metabolism*; D004789:Enzyme Activation; D005260:Female; D006520:Hepatitis, Animal / Q000201:enzymology* / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008822:Mice, Transgenic; D009961:Orosomucoid / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D000515:alpha 1-Antitrypsin / Q000494:pharmacology
chemical_list: D000209:Acute-Phase Proteins; D061945:Caspase Inhibitors; D009961:Orosomucoid; D019253:Proto-Oncogene Proteins c-bcl-2; D014409:Tumor Necrosis Factor-alpha; D000515:alpha 1-Antitrypsin; D000410:Alanine Transaminase; D020169:Caspases